Online forums for semaglutide and tirzepatide are full of posts describing something that seems to contradict how these medications are supposed to work: sudden, intense hunger weeks or months into treatment. Others describe plateaus, or even regain, while still taking the medication. These experiences are common enough to generate hundreds of comments per thread, and they point to a real gap in how GLP-1 therapy is understood outside the exam room.

GLP-1s Don’t Work the Same Way at Every Dose

Semaglutide and tirzepatide are approved for gradual dose titration for a reason. At lower doses, the appetite-suppressing effect is often modest. As the dose increases over weeks or months, most patients notice a stronger reduction in hunger signals. But titration isn’t linear for everyone. Some people plateau at a dose that worked initially, then find the effect fades — a phenomenon that has less to do with the drug ‘stopping working’ and more to do with the body adapting, along with changes in weight, metabolism, and sometimes injection technique or timing.

Why ‘Ravenous’ Happens

A subset of patients report a distinct rebound in hunger, sometimes described as more intense than before starting the medication. This can happen for several reasons: a missed or delayed dose, running lower on medication near the end of a dosing week, inadequate protein or fiber intake blunting satiety, sleep disruption, or simply reaching a dose that isn’t yet sufficient for that individual’s biology. GLP-1 receptor sensitivity varies from person to person, and there’s no universal dose that produces the same appetite response for everyone.

Plateaus Are Physiologic, Not a Failure

Weight loss on any GLP-1 medication is rarely a straight line down. As total body weight decreases, resting energy expenditure typically decreases too — the body needs fewer calories to maintain a smaller frame. This is a normal metabolic adaptation, not a sign the medication has stopped working. Plateaus often prompt a reassessment: is the current dose still appropriate, has nutrition or activity shifted, or is this simply a stabilization phase before further titration.

Why DIY Dosing Adjustments Are Risky

Faced with plateaus or hunger spikes, some patients are tempted to self-adjust — splitting doses, spacing injections further apart, or sourcing additional medication outside a clinical relationship. This bypasses the monitoring that makes titration safe. Dose changes should account for GI tolerance, other medications, kidney function, and individual response — data a physician tracks over time, not something reliably self-managed from a forum thread.

What Monitored Titration Actually Looks Like

In a clinical setting, dose adjustments are paired with regular check-ins: how’s appetite, GI tolerance, energy, and weight trend responding? Are there signs the current dose is too low, too high, or right but needs more time? This ongoing conversation is what separates supervised titration from guesswork, and it’s why unexplained hunger or a stalled plateau is worth a call to your prescriber rather than a dose change on your own.

The Takeaway

Hunger fluctuations and plateaus on GLP-1 medications are common, expected, and usually explainable — but they need a clinical eye to interpret correctly. If something feels off, that’s information for your care team, not a signal to experiment alone.